Drug fails to reduce diarrhea in patients receiving radiation therapy
Sulfasalazine, which is commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area, according to a new study. Also, the medication may be associated with a higher risk for diarrhea than a placebo when used during radiation therapy to the pelvis. These results were presented at the American Society of Radiation Oncology's 55th Annual Meeting in Atlanta, Georgia.
"Patients receiving radiation therapy in the pelvic region can experience diarrhea, which is a negative side effect of the therapy," said the study's lead author Robert Miller, MD, a radiation oncologist at Mayo Clinic in Rochester, Minnesota. Previous trials of sulfasalazine, which treats bowel inflammation, had found that it decreased diarrhea in patients during pelvic radiation therapy.
Miller led a 2-year, randomized, double-blind, placebo-controlled phase III clinical trial through the Alliance for Clinical Trials in Oncology to evaluate the effectiveness of sulfasalazine versus placebo in inflammation of the bowel during pelvic radiation therapy. The trial included 87 patients, with 78 patients evaluated for the primary endpoint, which was maximal severity of diarrhea up to six weeks after therapy, based on commonly accepted criteria. Patients enrolled in the study came from 24 institutions in the United States.
Patients received 1,000 milligrams of sulfasalazine or placebo orally, twice each day during radiation therapy and for 4 weeks after therapy. Patients completed bowel-function questionnaires weekly during therapy, afterward for 6 weeks and at 12 and 24 months after therapy. Health care providers graded each patient on the maximum severity and the duration of maximum severity of diarrhea, rectal bleeding, abdominal cramping, constipation, and tenesmus, which is the sensation of incomplete defecation.
Interim results from the study found a statistically significant excess of grade 3 diarrhea (passing seven or more stools per day) in patients receiving sulfasalazine versus placebo. The study was halted in May 2013 when researchers determined that it was unlikely sulfasalazine would show benefit.
"While previous research had suggested benefit for sulfasalazine, we were very surprised to find that patients receiving sulfasalazine experienced worse diarrhea than those receiving placebo," Miller said. "We now know that sulfasalazine will not help patients receiving radiation therapy in the pelvic region avoid diarrhea as a side effect of the therapy." Miller added that the study illustrates the need for large, phase III, randomized, controlled trials to better understand which drugs and therapies can help mitigate the negative side effects for patients receiving radiation therapy.